Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression array of DNMT1 inhibitor treated AML cell lines

ABSTRACT: Genome wide demethylation by DNMT1 inhibitor GSK3484862 results in up-regulation of epigenetically-silenced genes. Differential expression was perfomed for each cell line following DNMT1 inhibitor or vehicle treatment. Differentially epressed gene lists were submitted to gene set enrichment analysis (GSEA) to identify consistently changed pathways.

ORGANISM(S): Homo sapiens

PROVIDER: GSE134716 | GEO | 2022/12/31

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Expression array of DNMT1 inhibitor treated 3 AML cell lines

Project description:Genome wide demethylation by DNMT1 inhibitor GSK3484862 results in up-regulation of epigenetically-silenced genes Differential expression was perfomed for each cell line following DNMT1 inhibitor or vehicle treatment. Differentially epressed gene lists were submitted to gene set enrichment analysis (GSEA) to identify consistently changed pathways.

2022-12-31 | GSE134742 | GEO

Epic methylation arrays of DNMT1 inhibitor treated AML cell lines

Project description:Genome wide demethylation by DNMT1 inhibitor GSK3685032 results in up-regulation of epigenetically-silenced genes

2021-06-30 | GSE135205 | GEO

MethylationEPIC array of DNMT1 inhibitor treated AML cell lines - part II

Project description:Genome wide demethylation by DNMT1 inhibitor GSK3484862 results in up-regulation of epigenetically-silenced genes. Methylation was assayed for each cell line following DNMT1 inhibitor or vehicle treatment. Global methylation distributions were compared between treated and untreated samples.

2021-06-30 | GSE135206 | GEO

RNA-seq of DNMT1 inhibitor treated AML cell lines

Project description:Genome wide demethylation by DNMT1 inhibitors GSK3685032 results in up-regulation of epigenetically-silenced genes.

2021-06-30 | GSE135378 | GEO

RNA-seq of DNMT1 inhibitor treated AML cell lines

Project description:RNA-seq of DNMT1 inhibitor treated AML cell lines

| PRJNA558691 | ENA

Epic methylation arrays of DNMT1 inhibitor treated AML cell lines

Project description:Epic methylation arrays of DNMT1 inhibitor treated AML cell lines

| PRJNA557724 | ENA

MethylationEPIC array of DNMT1 inhibitor treated AML cell lines - part II

Project description:MethylationEPIC array of DNMT1 inhibitor treated AML cell lines - part II

| PRJNA557722 | ENA

A mutant DNMT1 enhances tumorigenicity with focal hypermethylation and global hypomethylation

Project description:Site-specific hypermethylation of tumor suppressor genes accompanied by genome-wide hypomethylation are epigenetic hallmarks of malignancy. However, molecular mechanisms that drive these linked changes in DNA methylation remain obscure. DNA methyltransferase 1 (DNMT1), the principle enzyme responsible for maintaining methylation patterns is commonly dysregulated in tumors. Replication foci targeting sequence (RFTS) is an N-terminal domain of DNMT1 that inhibits DNA-binding and catalytic activity, suggesting that RFTS deletion would result in gain of DNMT1 function. However, earlier data suggested that RFTS is required for DNMT1 activity. Here, we determined cellular consequences of RFTS deletion from DNMT1 in immortalized human bronchial epithelial cells. Compared to full-length DNMT1, ectopic expression of DNMT1- ?RFTS caused greater malignant transformation and enhanced promoter methylation that silenced DAPK and DUOX1 gene expression and increased intensity of promoter methylation across the genome. Strikingly, DNMT1-?RFTS also produced genomic hypomethylation and demethylation of Satellite 2 repeat sequences. Because deletion of RFTS is sufficient to induce focal hypermethylation and global hypomethylation in parallel, evidence suggests that the RFTS domain is a target responsible for epigenetic changes in cancer. DNA samples from HBEC3 cells transfected with vector control and HBEC3 cells with full-length and RFTS-deleted DNMT1 were assessed for genome-wide methylation using the microarray-based high resolution HpaII tiny fragment enriched by ligation-mediated PCR (HELP) assay.

2014-09-30 | E-GEOD-57829 | biostudies-arrayexpress

RFTS-deleted DNMT1 enhances tumorigenicity with focal hypermethylation and global hypomethylation

Project description:Site-specific hypermethylation of tumor suppressor genes accompanied by genome-wide hypomethylation are epigenetic hallmarks of malignancy. However, molecular mechanisms that drive these linked changes in DNA methylation remain obscure. DNA methyltransferase 1 (DNMT1), the principle enzyme responsible for maintaining methylation patterns is commonly dysregulated in tumors. Replication foci targeting sequence (RFTS) is an N-terminal domain of DNMT1 that inhibits DNA-binding and catalytic activity, suggesting that RFTS deletion would result in gain of DNMT1 function. However, earlier data suggested that RFTS is required for DNMT1 activity. Here, we determined cellular consequences of RFTS deletion from DNMT1 in immortalized human bronchial epithelial cells. Compared to full-length DNMT1, ectopic expression of DNMT1- ΔRFTS caused greater malignant transformation and enhanced promoter methylation that silenced DAPK and DUOX1 gene expression and increased intensity of promoter methylation across the genome. Strikingly, DNMT1-ΔRFTS also produced genomic hypomethylation and demethylation of Satellite 2 repeat sequences. Because deletion of RFTS is sufficient to induce focal hypermethylation and global hypomethylation in parallel, evidence suggests that the RFTS domain is a target responsible for epigenetic changes in cancer.

2014-09-30 | GSE57829 | GEO

Expression profiling and methylation analysis of DNMT1 inhibitor treated AML cell lines

Project description:Expression profiling and methylation analysis of DNMT1 inhibitor treated AML cell lines

| PRJNA557720 | ENA